6 must-reads for supply chain leaders this week

Here are six articles Becker's Hospital Review published in the last week, highlighting why drugmakers would welcome Amazon's pharmacy market entrance and Merck's $135M sales loss attributed to the NotPetya cyberattack.

1. Is Amazon also looking to enter the medical device business?
While the healthcare industry is full of speculation over Amazon's potential entrance into the pharmacy market, one analyst believes the retailer may be more interested in the medical device market. 

2. Merck attributes $135M in lost Q3 sales to NotPetya cyberattack
Merck & Co. released its third quarter earnings results Oct. 27. The company posted $10.32 billion in sales, down 2 percent from the $10.54 billion it reported during the same period last year. 

3. Supply chain tip of the day: How to maintain the medical supply chain amid natural disasters
"Every day, hospitals across the country receive shipments of critical medications and pharmaceutical products they need to treat patients," says Erin Horvath, senior vice president of distribution services at AmerisourceBergen. 

4. Why drugmakers would welcome Amazon's drug market entrance
Rumors of Amazon's potential entrance into the pharmacy market have already sent drug distributors' and retail pharmacies' stock falling. However, the drug industry would gladly welcome the move. 

5. FDA: EpiPen failures attributed to 7 deaths this year
EpiPen failures — specifically their inability to deploy correctly — caused seven patient deaths so far this year.

6. Study: Competition did not prevent rise in cancer drug prices after launch
The price of U.S. cancer drugs after they hit the market was not affected by new competition, new supplemental FDA approvals or new off-label indications.

More articles on supply chain:

FDA: EpiPen failures attributed to 7 deaths this year
HHS aids uninsured US Virgin Island residents in need of prescription drugs
Medline to acquire Centurion Medical Products: 4 things to know

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.